E-ISSN 2534-9821
 

Original Research 


Paclitaxel plus carboplatin as neoadjuvant chemotherapy prior to radical hysterectomy and pelvic lymphadenectomy for stage IB2-IIB cervical cancer: clinical efficacy and safety

Biswa Ranjan Routroy, Sailendra Narayan Parida, Lal Mohan Soy, Ashutosh Hota.

Abstract
Aim: To evaluate the effectiveness and side effects of the paclitaxel and carboplatin combination as neoadjuvant chemotherapy for locally advanced cervical cancer before radical hysterectomy and pelvic lymphadenectomy. Method: We selected patients with cervical cancer who having undergone neoadjuvant chemotherapy with paclitaxel and carboplatin followed by radical hysterectomy (NACT group) or only underwent primary radical surgery (PRS group) in Acharya Harihar Post Graduate Institute of Cancer, Cuttack. Data on toxicity, NACT response, surgical pathological factors, and survival were gathered and analysed. Result: The overall rate of participation (81/11) for the NACT group was 71.2%. 15.6% patients experienced total remission. The response to NACT was better in tumours that were well differentiated (P=0.010). The most frequent adverse event was myelosuppression (51.6%), although severe adverse effects were infrequent (3.3%). 40 months made up the average follow-up time (range, 5-74). When contrasted with non-NACT respondents and individuals in the PRS group, the NACT responders had considerably longer OS and PFS. Conclusions: Although LACC patients respond to the chemotherapeutic drugs, they may profit from neoadjuvant chemotherapy with paclitaxel and carboplatin.

Key words: paclitaxel plus carboplatin Neoadjuvant chemotherapy, cervical cancer, prognosis


 
ARTICLE TOOLS
Abstract
PDF Fulltext
How to cite this articleHow to cite this article
Citation Tools
Related Records
 Articles by Biswa Ranjan Routroy
Articles by Sailendra Narayan Parida
Articles by Lal Mohan Soy
Articles by Ashutosh Hota
on Google
on Google Scholar


How to Cite this Article
Pubmed Style

Routroy BR, Parida SN, Soy LM, Hota A. Paclitaxel plus carboplatin as neoadjuvant chemotherapy prior to radical hysterectomy and pelvic lymphadenectomy for stage IB2-IIB cervical cancer: clinical efficacy and safety. Int J Med Rev Case Rep. 2022; 6(16): 54-58. doi:10.5455/IJMRCR.172-1667475903


Web Style

Routroy BR, Parida SN, Soy LM, Hota A. Paclitaxel plus carboplatin as neoadjuvant chemotherapy prior to radical hysterectomy and pelvic lymphadenectomy for stage IB2-IIB cervical cancer: clinical efficacy and safety. https://www.mdpub.net/?mno=127109 [Access: January 14, 2023]. doi:10.5455/IJMRCR.172-1667475903


AMA (American Medical Association) Style

Routroy BR, Parida SN, Soy LM, Hota A. Paclitaxel plus carboplatin as neoadjuvant chemotherapy prior to radical hysterectomy and pelvic lymphadenectomy for stage IB2-IIB cervical cancer: clinical efficacy and safety. Int J Med Rev Case Rep. 2022; 6(16): 54-58. doi:10.5455/IJMRCR.172-1667475903



Vancouver/ICMJE Style

Routroy BR, Parida SN, Soy LM, Hota A. Paclitaxel plus carboplatin as neoadjuvant chemotherapy prior to radical hysterectomy and pelvic lymphadenectomy for stage IB2-IIB cervical cancer: clinical efficacy and safety. Int J Med Rev Case Rep. (2022), [cited January 14, 2023]; 6(16): 54-58. doi:10.5455/IJMRCR.172-1667475903



Harvard Style

Routroy, B. R., Parida, . S. N., Soy, . L. M. & Hota, . A. (2022) Paclitaxel plus carboplatin as neoadjuvant chemotherapy prior to radical hysterectomy and pelvic lymphadenectomy for stage IB2-IIB cervical cancer: clinical efficacy and safety. Int J Med Rev Case Rep, 6 (16), 54-58. doi:10.5455/IJMRCR.172-1667475903



Turabian Style

Routroy, Biswa Ranjan, Sailendra Narayan Parida, Lal Mohan Soy, and Ashutosh Hota. 2022. Paclitaxel plus carboplatin as neoadjuvant chemotherapy prior to radical hysterectomy and pelvic lymphadenectomy for stage IB2-IIB cervical cancer: clinical efficacy and safety. International Journal of Medical Reviews and Case Reports, 6 (16), 54-58. doi:10.5455/IJMRCR.172-1667475903



Chicago Style

Routroy, Biswa Ranjan, Sailendra Narayan Parida, Lal Mohan Soy, and Ashutosh Hota. "Paclitaxel plus carboplatin as neoadjuvant chemotherapy prior to radical hysterectomy and pelvic lymphadenectomy for stage IB2-IIB cervical cancer: clinical efficacy and safety." International Journal of Medical Reviews and Case Reports 6 (2022), 54-58. doi:10.5455/IJMRCR.172-1667475903



MLA (The Modern Language Association) Style

Routroy, Biswa Ranjan, Sailendra Narayan Parida, Lal Mohan Soy, and Ashutosh Hota. "Paclitaxel plus carboplatin as neoadjuvant chemotherapy prior to radical hysterectomy and pelvic lymphadenectomy for stage IB2-IIB cervical cancer: clinical efficacy and safety." International Journal of Medical Reviews and Case Reports 6.16 (2022), 54-58. Print. doi:10.5455/IJMRCR.172-1667475903



APA (American Psychological Association) Style

Routroy, B. R., Parida, . S. N., Soy, . L. M. & Hota, . A. (2022) Paclitaxel plus carboplatin as neoadjuvant chemotherapy prior to radical hysterectomy and pelvic lymphadenectomy for stage IB2-IIB cervical cancer: clinical efficacy and safety. International Journal of Medical Reviews and Case Reports, 6 (16), 54-58. doi:10.5455/IJMRCR.172-1667475903